GPW Stock Research - 4 Value Investing Masters
Analyze Warsaw Stock Exchange stocks through Buffett, Munger, Duan Yongping and Li Lu lenses - ending in PLN buy/sell ranges.
Free
Works with the AI Agents you already use
GPW Stock Research - 4 Value Investing Masters
Example session with this skill installed
Analyze XTB using the four masters team framework
- Read your context and instructions
- Compiled the gpw stock research
XTB S.A. (GPW: XTB) — four masters team analysis
Date: 2026-07-07
Price: 122.58 PLN (52-week high)
Market cap: 14.41 bn PLN (117,569,251 × 122.58, computed by hand)
1. One-sentence conclusion
XTB is a superbly run, highly profitable machine for collecting spreads from retail CFD speculators (~90% of revenue) with a real but still marginal investing pivot — a good company at the wrong price at the wrong time: at 122.58 PLN you buy a cyclical, regulation-exposed business at a growth multiple, at a 52-week high, with no margin of safety.
2. Ratings
| Lens | Master | Rating | Key judgment |
|---|---|---|---|
| Business essence | Duan Yongping | ★★★☆☆ | Two businesses in one app: a high-margin "toll" on CFD speculators (94% of revenue, ~72–80% of clients lose money — XTB KID ~74%) plus a small, low-margin investing pivot (stocks/ETF/IKE ~4%). Excellently run, but the core is ethically borderline and unpredictable. |
| Financials & valuation | Buffett | ★★☆☆☆ | Quality ★3 (ROE 25–53%, ~2.6 bn PLN net cash, no debt), valuation ★2: base value ~88 PLN, price 122.58 = ~40% premium, zero margin of safety. |
| Risk / inversion | Munger | ★★☆☆☆ | 22× P/E vs peers (Plus500 ~11–15×, IG ~10–17×) for a business with HIGHER earnings volatility and regulatory concentration. Fortress balance sheet rules out ★1, but the risk of lasting disappointment is high. |
| 10-year certainty | Li Lu | ★★☆☆☆ | Profit engine (CFD ~90%) runs against ESMA/KNF regulation; pivot credible but unproven in the P&L. 10-year test = "don't know" = don't buy. Management ★3. |
Composite: 2.3 / 5 — high operating quality, wrong price, high cyclical-regulatory risk, low 10-year certainty.
3. Tensions between the masters
Quality vs cyclicality. Buffett sees an excellent business bought at a bad price — the defect is in the price, not the company. Munger flips it: XTB is a cyclical market-maker, and London prices Plus500/IG at ~11–15× precisely because they are cyclical and regulation-capped. So XTB isn't cheap relative to growth, it's
expensive relative to its true peer group — multiple compression to peers alone means −35% to −50%.
The profit engine. Earnings are real in cash but extremely unrepeatable (10× quarterly swing: Q3'25 53.2 m → Q1'26 ~535 m PLN). 88.5% of the record Q1'26 came from commodity volatility (gold/silver) — a windfall, not a new base. All four agree: anchoring on TTM 985 m PLN is a mistake; calendar 2025 profit was
643.8 m PLN (−24.9% y/y).
Full agreement: bulletproof balance sheet; no margin of safety at 122.58; "I earn when the client loses" is a structural regulatory risk (20 m PLN KNF fine = start of a trend); the founder keeps selling (43.78% → 35.78%).
4. Tiered recommendation
Base intrinsic value (normalized profit ~800–900 m PLN through the cycle):
~88 PLN/share. Bear ~45–46 PLN, bull ~140–157 PLN.
| Strategy | At 122.58 PLN | Buy below | Hold | Sell above |
|---|---|---|---|---|
| Aggressive (believes in lasting 30%+ ROE) | HOLD (near sell zone) | 88 PLN | 88–140 | 140 PLN |
| Moderate (base + ~20% margin) | OVERVALUED / trim | 72 PLN | 72–118 | 118 PLN |
| Conservative (weights cyclicality + CFD/ESMA risk) | AVOID / sell | 60 PLN | 60–95 | 95 PLN |
Net: no buying opportunity. Entering today means paying for the peak of the volatility cycle.
5. Thesis falsification conditions
The bull case breaks if any of these happen:
- ESMA/KNF cuts leverage on commodity CFDs (now 10:1) or bans the product class.
- Another year of net margin <30% on rising revenue (2025 costs +48% vs revenue +14.6%).
- Stocks/ETF + interest income stay below ~10% of revenue for 2–3 years.
- 2–3 more flat quarters like Q3'25 (~50 m PLN profit).
- The founder drops below the declared ~30% stake or speeds up selling.
6. Mirror test (thesis in 5 sentences)
XTB earns ~90% from spreads on retail CFD speculators, most of whom lose money — highly profitable but extremely dependent on market volatility and under lasting ESMA/KNF pressure. It is genuinely pivoting toward long-term investing (2.16 m clients, +64% y/y), but that segment is <4% of revenue and structurally low-margin. At 122.58 PLN the market prices XTB as a growth compounder (22× 2025 earnings, 5.67× book), paying a 50–100% premium to similar peers by extrapolating a commodity windfall quarter. Base value is ~88 PLN, so there's no margin of safety, and the founder is selling.
Watchlist, not a buy at 122 PLN.
Next steps
- Saved:
reports/XTB/XTB-analysis-20260707.md+ thesis trackerXTB-thesis.md - Run
/gpw-thesis XTBafter each quarterly report to check falsification conditions - Price alert: re-run
/gpw-analyze XTBif the price drops below 95 PLN
Research tool, not investment advice. All ratios computed with financial_rigor.py, not mental math.
Connects securely to your tools. The creator never sees your data.
About this skill
Turn your agent into a disciplined equity analyst for the Warsaw Stock Exchange.
14 research playbooks built on four value-investing lenses — Duan Yongping (is this a good business?), Buffett (numbers and valuation), Munger (how this company dies), Li Lu (the 10-year test) — with hard anti-bias rules:
- every key number from 2 independent sources, market cap recomputed by hand
- exact decimal arithmetic via bundled Python tools, no mental math
- missing data is "NO DATA", never a guess
- every verdict ends in tiered PLN ranges (aggressive / moderate / conservative) — no fence-sitting
What you can ask:
- "analyze XTB" — full four-lens report with buy/sell ranges (10–20 min)
- "scan the watchlist for buy signals" — momentum breakouts confirmed by fundamentals
- "review my portfolio" — SELL / BUY / WAIT orders with price levels
- "does my thesis on CDR still hold?", "why did KGH drop today?", "read PKN's quarterly results"
Research tool, not investment advice. Open source (MIT): github.com/hkn-33/gpw-research-workshop
Find more skills like this on the Claude Skills Marketplace, the Codex Skills Marketplace and the Gemini Skills Marketplace, or browse All Claude Skills.
GPW only. Fundamentals scraped from public Polish sites - quality depends on their coverage. Small caps get "researchability C" (first-principles mode). Not investment advice; executes no trades
How to use
- 1
Connect your agent to the Agensi MCP
Copy the prompt and paste it into Claude, ChatGPT, Cursor or any agent that supports MCP. It sets up the connection for you. Manual setup
- 2
Sign in to Agensi
Your agent shows a sign-in link. Sign in and click Allow.
- 3
Ask for what you need
Your agent loads this skill and uses it on your task. It always asks before buying a skill.
Reviews
No reviews yet
Be one of the first to try it. Every listed skill goes through the trust checks below.
Security scanned
Checked by our 8-point scan before listing
Fresh listing
Recently published to Agensi
Free to use
No account required to browse
Trust & safety
Security scan
Security scan passed 23 days ago
- Free with an Agensi account
- Accounts
Yahoo
- Software
Python 3
Permissions
Allowed Hosts
Shell runs bundled Python tools. Network: public quotes from Yahoo Finance + web pages of public financial sites. Writes reports to reports/ and reads your portfolio.md. No API keys, no credentials.